{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T04:27:08Z","timestamp":1784608028530,"version":"3.55.0"},"reference-count":31,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2014,12,15]],"date-time":"2014-12-15T00:00:00Z","timestamp":1418601600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0112401","type":"journal-article","created":{"date-parts":[[2014,12,15]],"date-time":"2014-12-15T18:46:22Z","timestamp":1418669182000},"page":"e112401","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":26,"title":["Instability of Misoprostol Tablets Stored Outside the Blister: A Potential Serious Concern for Clinical Outcome in Medical Abortion"],"prefix":"10.1371","volume":"9","author":[{"given":"Veronique","family":"Berard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Fiala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Cameron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Bombas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirella","family":"Parachini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Gemzell-Danielsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2014,12,15]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1067\/mob.2000.107948","article-title":"Medical abortion regimens: historical context and overview","volume":"183","author":"M Creinin","year":"2000","journal-title":"Am J Obstet Gynecol"},{"issue":"2","key":"ref2","first-page":"316","article-title":"Misoprostol for women\u2019s health: A review","volume":"99","author":"K Blanchard","year":"2002","journal-title":"Am J Obstet Gynecol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"S155","DOI":"10.1016\/j.ijgo.2007.09.002","article-title":"Misoprostol for Reproductive Health","volume":"99","author":"D Shaw","year":"2007","journal-title":"Int J of Gynecology & Obstetrics"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0020-7292(96)02815-9","article-title":"Misoprostol in the management of missed abortion","volume":"56","author":"Y Herabutya","year":"1997","journal-title":"Int J Gynecol Obstet"},{"key":"ref5","first-page":"248","article-title":"A medical approach to management of spontaneous abortion using misoprostol. Extending misoprostol treatment to a maximum of 48 hours can further improve evacuation of retained products of conception in spontaneous abortion","volume":"76","author":"T Chung","year":"1997","journal-title":"Acta Obstet Gynecol Scand"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/S0029-7844(97)00111-7","article-title":"Absorption kinetics of misoprostol with oral or vaginal administration","volume":"90","author":"M Zieman","year":"1997","journal-title":"Obstet Gynecol"},{"key":"ref7","first-page":"275","article-title":"Comparison between oral and vaginal administration of misoprostol on uterine contractility","volume":"93","author":"KG Danielsson","year":"1999","journal-title":"Obstet Gynecol"},{"key":"ref8","first-page":"67S","article-title":"The efficacy of a 600-microgram misoprostol regimen for the evacuation of missed abortions","volume":"97","author":"WA Mc Creath","year":"2001","journal-title":"Obstet Gynecol"},{"issue":"2","key":"ref9","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.ijgo.2012.12.009","article-title":"WHO recommendations for misoprostol use for obstetric and gynecologic indications","volume":"121","author":"J Tang","year":"2013","journal-title":"Int J of Gynecology & Obstetrics"},{"issue":"8","key":"ref10","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1111\/j.1471-0528.2005.00638.x","article-title":"A randomised controlled trial of mifepristone in combination with misoprostol administered sublingually or vaginally for medical abortion up to 13 weeks of gestation","volume":"112","author":"H Hamoda","year":"2005","journal-title":"British Journal of Obstetrics and Gynaecology"},{"issue":"1","key":"ref11","unstructured":"Kulier R, Kapp N, G\u00fclmezoglu AM, Hofmeyr GJ, Cheng L, <etal>et al<\/etal>.<bold>.<\/bold> (2011) Medical methods for first trimester abortion. Cochrane Database of Systematic Reviews ((<issue>1<\/issue>):): CD002855."},{"key":"ref12","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1093\/humrep\/16.9.1849","article-title":"Medical management of early fetal demise using a combination of mifepristone and misoprostol","volume":"16","author":"PT Wagaarachchi","year":"2001","journal-title":"Hum Reprod"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"44S","DOI":"10.1067\/mob.2000.107950","article-title":"Abortion with mifepristone and misoprostol: regimens, efficacy, acceptability and future directions","volume":"183","author":"EP Newhall","year":"2000","journal-title":"Am J Obstet Gynecol"},{"key":"ref14","first-page":"184","article-title":"The mifepristone-misoprostol regimen for early medical abortion","volume":"1","author":"C Ellertson","year":"2001","journal-title":"Current Women\u2019s Health Reports"},{"key":"ref15","unstructured":"National Abortion Federation (2002) Early medical abortion with mifepristone and other agents: Overview and protocol recommendations. Washington, DC: NAF."},{"key":"ref16","first-page":"220","article-title":"The efficacy and acceptability of mifepristone medical abortion with home administration of misoprostol provided by private providers linked with the hospital; a prospective study of 433 patients","volume":"33","author":"P Faucher","year":"2005","journal-title":"Gyn\u00e9cologie Obst\u00e9trique & Fertilit\u00e9"},{"key":"ref17","unstructured":"Cervagem (2005) Summary of Product Characteristics Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.medicines.org.uk\/emc\/medicine\/3968\/spc\" xlink:type=\"simple\">http:\/\/www.medicines.org.uk\/emc\/medicine\/3968\/spc<\/ext-link>. Accessed 10 October 2013."},{"issue":"11","key":"ref18","doi-asserted-by":"crossref","first-page":"114S","DOI":"10.1007\/BF01309395","article-title":"Chemistry and Synthetic Development of Misoprostol","volume":"30","author":"PW Collins","year":"1985","journal-title":"Digestive Diseases and Sciences"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/jps.2600810209","article-title":"Misoprostol dehydratation kinetics in aquaeous solution in presence of hydroxypropyl methylcellulose","volume":"81","author":"D Toledo-Velasquez","year":"1992","journal-title":"J Pharm Sci"},{"key":"ref20","unstructured":"EMA (08\/2003) Note for guidance on stability testing: stability testing of new drug substances and products. Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2009\/09\/WC500002651.pdf\" xlink:type=\"simple\">http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2009\/09\/WC500002651.pdf<\/ext-link>. Accessed 28 March 2014."},{"key":"ref21","first-page":"5107","article-title":"M\u00e9thodes de dosage: 2.5.12 Semi micro-dosage de l\u2019eau. In Pharmacop\u00e9e europ\u00e9enne 7.6: Direction de l\u2019\u00e9valuation de la qualit\u00e9 du m\u00e9dicament, Conseil de l\u2019Europe, Strasbourg, France","volume":"1","year":"2013","journal-title":"Tome"},{"key":"ref22","first-page":"291","article-title":"M\u00e9thodes pharmacotechniques: 2.9.5 uniformit\u00e9 de masse des pr\u00e9parations unidoses In Pharmacop\u00e9e europ\u00e9enne 7.0: Direction de l\u2019\u00e9valuation de la qualit\u00e9 du m\u00e9dicament, Conseil de l\u2019Europe, Strasbourg, France","volume":"1","year":"2011","journal-title":"Tome"},{"key":"ref23","first-page":"292","article-title":"M\u00e9thode pharmacotechniques: 2.9.7 Friabilit\u00e9 des comprim\u00e9s non enrob\u00e9s. In Pharmacop\u00e9e europ\u00e9enne 7.0: Direction de l\u2019\u00e9valuation de la qualit\u00e9 du m\u00e9dicament, Conseil de l\u2019Europe, Strasbourg, France","volume":"1","year":"2011","journal-title":"Tome"},{"key":"ref24","first-page":"293","article-title":"M\u00e9thode pharmacotechniques: 2.9.8 R\u00e9sistance \u00e0 la rupture des comprim\u00e9s. In Pharmacop\u00e9e europ\u00e9enne 7.0: Direction de l\u2019\u00e9valuation de la qualit\u00e9 du m\u00e9dicament, Conseil de l\u2019Europe, Strasbourg, France","volume":"1","year":"2011","journal-title":"Tome"},{"key":"ref25","first-page":"2704","article-title":"Monographie 04\/2010:1731. Misoprostol. In Pharmacop\u00e9e europ\u00e9enne 7.0: Direction de l\u2019\u00e9valuation de la qualit\u00e9 du m\u00e9dicament, Conseil de l\u2019Europe, Strasbourg, France","volume":"2","year":"2011","journal-title":"Tome"},{"issue":"11","key":"ref26","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1023\/A:1015996712794","article-title":"Stabilization of Misoprostol with HydroxypropylMethylcellulose (HPMC) against degradation by water","volume":"7","author":"TT Kararli","year":"1990","journal-title":"Pharmaceutical research"},{"key":"ref27","unstructured":"Exelgyn (2013) SmPC Mifegyne 200 mg Tablet. April 2013."},{"key":"ref28","unstructured":"RCOG (2011) The care of women requesting induced abortion. Evidence-based clinical guideline number 7. Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.rcog.org.uk\/files\/rcog-corp\/Abortion%20guideline_web_1.pdf\" xlink:type=\"simple\">http:\/\/www.rcog.org.uk\/files\/rcog-corp\/Abortion%20guideline_web_1.pdf<\/ext-link>. Accessed 27 March 2014."},{"issue":"3","key":"ref29","first-page":"281","article-title":"Mechanism of misoprostol stabilization in hydroxypropyl methylcellulose","volume":"87","author":"TT Kararli","year":"2004","journal-title":"Int J Gynaecol Obstet"},{"key":"ref30","first-page":"1","article-title":"Analytical methodology to determine the potency and quality of misoprostol tablets","volume":"2012","author":"SA Carr","year":"2012","journal-title":"Appropriate Healthcare Technologies for Developing Countries, 7th International Conference on 8\u201319 Sept"},{"issue":"5","key":"ref31","first-page":"795","article-title":"Randomized trial to determine optimal dose of vaginal misoprostol for preabortion cervical priming","volume":"92","author":"K1 Singh","year":"1998","journal-title":"Obstet Gynecol"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0112401","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T17:58:01Z","timestamp":1589047081000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0112401"}},"subtitle":[],"editor":[{"given":"Shannon M.","family":"Hawkins","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2014,12,15]]},"references-count":31,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2014,12,15]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0112401","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12,15]]}}}